Outlook Therapeutics, Inc.
corporate_fare Company Profile
Outlook Therapeutics, Inc. (NASDAQ:OTLK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 60 items for OTLK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 13 rated 8 or above. Recent SEC coverage for OTLK spans 8-K, 10-Q, SCHEDULE 13D/A, 4.
Recent high-impact activity:
- Outlook Therapeutics Receives Nasdaq Bid-Price Deficiency Notice, Must Regain $1.00 by March 24, 2027
- Outlook Therapeutics Sets $485 Per Vial Wholesale Price for LYTENAVA
- Outlook Therapeutics Q3 10-Q: Going Concern Warning and $51M Dilutive Offering
- Outlook Therapeutics Plans $55M Offering at $0.99 to Fund LYTENAVA Launch
- GMS Ventures Invests $2.5M in Outlook Therapeutics' $55M Offering
Financial Snapshot
Short Interest & Short Volume
10.10 days to coverFINRA reported short interest of 35,546,027 shares in OTLK as of the October 30, 2026 settlement, a 9.1% increase from the prior period — about 10.1 days to cover at its recent average daily volume. On November 20, 2026, 50.4% of OTLK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for OTLK, detected from its recent SEC filings · based on capital-structure filings through 2026-08-14.
Public Offering Priced · Net Proceeds and Use
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →